Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Combined With Pertuzumab and Chemotherapy”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Not applicableUnknownNCT05188495
What this trial is testing

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

Who this might be right for
HER2-positive Metastatic Breast CancerPreviously Treated With TrastuzumabTrastuzumab Combined With Pertuzumab and Chemotherapy
Peking University Cancer Hospital & Institute 60
Not applicableStudy completedNCT07115095
What this trial is testing

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Nanlin Li 98
Large-scale testing (Phase 3)Looking for participantsNCT05256225
What this trial is testing

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Who this might be right for
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI) 360
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Large-scale testing (Phase 3)Looking for participantsNCT07441460
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Who this might be right for
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 1,800
Testing effectiveness (Phase 2)Ended earlyNCT02000596
What this trial is testing

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Who this might be right for
Metastatic Breast Cancer
University of Maryland, Baltimore 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT04172259
What this trial is testing

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Who this might be right for
Breast CancerNeoadjuvant Chemotherapy
Sun Yat-sen University 156
Testing effectiveness (Phase 2)Study completedNCT00976989
What this trial is testing

Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Testing effectiveness (Phase 2)Ended earlyNCT04108858
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Positive Breast CarcinomaMetastatic Breast Carcinoma
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Ended earlyNCT03101748
What this trial is testing

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Breast Inflammatory CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast Carcinoma+5 more
M.D. Anderson Cancer Center 34
Large-scale testing (Phase 3)WithdrawnNCT06884254
What this trial is testing

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

Who this might be right for
Early Breast Cancer
EirGenix, Inc.
Large-scale testing (Phase 3)Study completedNCT01774786
What this trial is testing

Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 780
Large-scale testing (Phase 3)Study completedNCT02586025
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Who this might be right for
Breast Cancer
Hoffmann-La Roche 329
Large-scale testing (Phase 3)Study completedNCT04024462
What this trial is testing

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Hoffmann-La Roche 200
Large-scale testing (Phase 3)Active Not RecruitingNCT04193059
What this trial is testing

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 1,560
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Large-scale testing (Phase 3)Study completedNCT03493854
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Looking for participantsNCT07108127
What this trial is testing

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

Who this might be right for
Rectal CancerHER2-positive
Peking Union Medical College Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07340398
What this trial is testing

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University 200
Testing effectiveness (Phase 2)Study completedNCT01461057
What this trial is testing

Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 30
Load More Results